share_log

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4:持股變動聲明-董事 Lewis-Hall Freda C
美股SEC公告 ·  12/21 06:10

Moomoo AI 已提取核心訊息

Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall與Conduit Pharmaceuticals有關,已報告一項計劃於2024年12月18日進行的交易。該交易的性質和細節在當前的申報中尚未披露。報告人的地址列爲4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。雖然申報中指明瞭一個未來事件,但並沒有具體說明所涉及的證券類型或交易數量。Lewis-Hall與發行人之間的關係在此公告中沒有明確說明。
Freda C Lewis-Hall與Conduit Pharmaceuticals有關,已報告一項計劃於2024年12月18日進行的交易。該交易的性質和細節在當前的申報中尚未披露。報告人的地址列爲4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。雖然申報中指明瞭一個未來事件,但並沒有具體說明所涉及的證券類型或交易數量。Lewis-Hall與發行人之間的關係在此公告中沒有明確說明。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息